Target Gene/Pathway
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
| No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * [Number of genes] |
KEGG DRUG * | DrugBank | Disease ID * [Number of diseases] |
| 1 | Adipocytokine signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 2 | African trypanosomiasis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 3 | AGE-RAGE signaling pathway in diabetic complications |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 4 | Allograft rejection |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 5 | Alzheimer disease |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 6 | Amoebiasis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 7 | Amyotrophic lateral sclerosis (ALS) |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 8 | Antifolate resistance |
[2] DHFR, DHFR2 | D00142 | Methotrexate | [33] 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
| D02115 | |||||
| [1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 9 | Antigen processing and presentation |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 10 | Apoptosis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 11 | Asthma |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 12 | C-type lectin receptor signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 13 | cGMP-PKG signaling pathway |
[1] OPRD1 | D02095 | Naltrexone | [11] 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
| D05113 | |||||
| 14 | Chagas disease (American trypanosomiasis) |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 15 | Complement and coagulation cascades |
[1] C5AR1 | D11093 | Avacopan | [4] 43, 44, 222, 223 |
| 16 | Cytokine-cytokine receptor interaction |
[1] IL6R | D02596 | Tocilizumab | [16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| [1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| [1] TNFSF13B | D03068 | Belimumab | [8] 11, 43, 44, 46, 49, 51, 53, 222 | ||
| 17 | Dilated cardiomyopathy (DCM) |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 18 | Drug metabolism - other enzymes |
[2] IMPDH1, IMPDH2 | D00752 | Mycophenolate mofetil | [32] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
| D05094 | |||||
| D05095 | |||||
| D05096 | Mycophenolic acid | [34] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 | |||
| 19 | EGFR tyrosine kinase inhibitor resistance |
[1] IL6R | D02596 | Tocilizumab | [16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 20 | Epstein-Barr virus infection |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 21 | Estrogen signaling pathway |
[1] OPRM1 | D02095 | Naltrexone | [11] 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
| D05113 | |||||
| 22 | Fc epsilon RI signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 23 | Fluid shear stress and atherosclerosis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 24 | Folate biosynthesis |
[2] DHFR, DHFR2 | D00142 | Methotrexate | [33] 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
| D02115 | |||||
| 25 | Graft-versus-host disease |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 26 | Hematopoietic cell lineage |
[1] IL6R | D02596 | Tocilizumab | [16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| [1] MS4A1 | D02994 | Rituximab | [42] 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 | ||
| [1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 27 | Hepatitis B |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 28 | Hepatitis C |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 29 | Herpes simplex virus 1 infection |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 30 | HIF-1 signaling pathway |
[1] IL6R | D02596 | Tocilizumab | [16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 31 | Human cytomegalovirus infection |
[1] IL6R | D02596 | Tocilizumab | [16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| [1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 32 | Human immunodeficiency virus 1 infection |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 33 | Human papillomavirus infection |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 34 | Human T-cell leukemia virus 1 infection |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 35 | Hypertrophic cardiomyopathy (HCM) |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 36 | IL-17 signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 37 | Inflammatory bowel disease (IBD) |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 38 | Influenza A |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 39 | Insulin resistance |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 40 | Intestinal immune network for IgA production |
[1] TNFSF13B | D03068 | Belimumab | [8] 11, 43, 44, 46, 49, 51, 53, 222 |
| 41 | JAK-STAT signaling pathway |
[1] IL6R | D02596 | Tocilizumab | [16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 42 | Legionellosis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 43 | Leishmaniasis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 44 | Malaria |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 45 | MAPK signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 46 | Metabolic pathways |
[2] DHFR, DHFR2 | D00142 | Methotrexate | [33] 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
| D02115 | |||||
| [2] IMPDH1, IMPDH2 | D00752 | Mycophenolate mofetil | [32] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | ||
| D05094 | |||||
| D05095 | |||||
| D05096 | Mycophenolic acid | [34] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 | |||
| 47 | Morphine addiction |
[1] OPRM1 | D02095 | Naltrexone | [11] 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
| D05113 | |||||
| 48 | mTOR signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 49 | Natural killer cell mediated cytotoxicity |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 50 | Necroptosis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 51 | Neuroactive ligand-receptor interaction |
[1] C5AR1 | D11093 | Avacopan | [4] 43, 44, 222, 223 |
| [1] NR3C1 | D00407 | Methylprednisolone | [36] 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 | ||
| D00751 | |||||
| D00979 | |||||
| D05000 | |||||
| D05001 | |||||
| D05002 | |||||
| D00472 | Prednisolone | [38] 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 | |||
| D00980 | |||||
| D00981 | |||||
| D00982 | |||||
| D01239 | |||||
| D01998 | |||||
| D02156 | |||||
| D03301 | |||||
| D00473 | Prednisone | [44] 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 | |||
| D00385 | Triamcinolone | [18] 6, 10, 13, 35, 40, 41, 42, 43, 44, 45, 46, 56, 70, 90, 96, 97, 226, 298 | |||
| D00983 | |||||
| D00984 | |||||
| D00985 | |||||
| D06216 | |||||
| [3] OPRD1, OPRK1, OPRM1 | D02095 | Naltrexone | [11] 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 | ||
| D05113 | |||||
| 52 | NF-kappa B signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| [1] TNFSF13B | D03068 | Belimumab | [8] 11, 43, 44, 46, 49, 51, 53, 222 | ||
| 53 | NOD-like receptor signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 54 | Non-alcoholic fatty liver disease (NAFLD) |
[1] IL6R | D02596 | Tocilizumab | [16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| [1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 55 | One carbon pool by folate |
[2] DHFR, DHFR2 | D00142 | Methotrexate | [33] 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
| D02115 | |||||
| 56 | Osteoclast differentiation |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 57 | Pathogenic Escherichia coli infection |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 58 | Pathways in cancer |
[1] IL6R | D02596 | Tocilizumab | [16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 59 | Pertussis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 60 | PI3K-Akt signaling pathway |
[1] IL6R | D02596 | Tocilizumab | [16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 61 | Proteoglycans in cancer |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 62 | Purine metabolism |
[2] IMPDH1, IMPDH2 | D00752 | Mycophenolate mofetil | [32] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
| D05094 | |||||
| D05095 | |||||
| D05096 | Mycophenolic acid | [34] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 | |||
| 63 | Rheumatoid arthritis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| [1] TNFSF13B | D03068 | Belimumab | [8] 11, 43, 44, 46, 49, 51, 53, 222 | ||
| 64 | RIG-I-like receptor signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 65 | Shigellosis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 66 | Sphingolipid signaling pathway |
[1] OPRD1 | D02095 | Naltrexone | [11] 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
| D05113 | |||||
| [1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 67 | Staphylococcus aureus infection |
[1] C5AR1 | D11093 | Avacopan | [4] 43, 44, 222, 223 |
| 68 | Systemic lupus erythematosus |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 69 | T cell receptor signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 70 | TGF-beta signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 71 | Th17 cell differentiation |
[1] IL6R | D02596 | Tocilizumab | [16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 72 | TNF signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 73 | Toll-like receptor signaling pathway |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 74 | Toxoplasmosis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 75 | Tuberculosis |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 76 | Type I diabetes mellitus |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 77 | Type II diabetes mellitus |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 78 | Viral protein interaction with cytokine and cytokine receptor |
[1] IL6R | D02596 | Tocilizumab | [16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| [1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 79 | Yersinia infection |
[1] TNF | D02598 | Infliximab | [23] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |